| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Non-Small-Cell Lung | 36 | 2024 | 5582 | 3.380 |
Why?
|
| Lung Neoplasms | 49 | 2024 | 12039 | 3.180 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 17 | 2024 | 1404 | 2.600 |
Why?
|
| Kelch-Like ECH-Associated Protein 1 | 7 | 2024 | 118 | 1.620 |
Why?
|
| Drug Resistance, Neoplasm | 9 | 2024 | 5417 | 1.080 |
Why?
|
| Mutation | 26 | 2024 | 15917 | 0.870 |
Why?
|
| Piperazines | 3 | 2021 | 2145 | 0.800 |
Why?
|
| CTLA-4 Antigen | 1 | 2024 | 677 | 0.710 |
Why?
|
| ErbB Receptors | 6 | 2024 | 2376 | 0.590 |
Why?
|
| B7-H1 Antigen | 11 | 2024 | 1098 | 0.590 |
Why?
|
| Pyridines | 2 | 2021 | 1313 | 0.570 |
Why?
|
| Pyrimidines | 5 | 2024 | 3671 | 0.560 |
Why?
|
| Carbazoles | 1 | 2016 | 89 | 0.530 |
Why?
|
| NF-E2-Related Factor 2 | 6 | 2023 | 256 | 0.510 |
Why?
|
| ras Proteins | 3 | 2015 | 804 | 0.460 |
Why?
|
| Antineoplastic Agents | 6 | 2023 | 14638 | 0.410 |
Why?
|
| Acrylamides | 3 | 2024 | 68 | 0.410 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2016 | 677 | 0.410 |
Why?
|
| Germ-Line Mutation | 2 | 2024 | 1101 | 0.400 |
Why?
|
| Protein Kinase Inhibitors | 4 | 2023 | 4965 | 0.400 |
Why?
|
| Immunotherapy | 8 | 2024 | 3561 | 0.390 |
Why?
|
| BRCA2 Protein | 2 | 2011 | 380 | 0.390 |
Why?
|
| Genome, Human | 1 | 2019 | 1896 | 0.370 |
Why?
|
| Piperidines | 1 | 2016 | 1099 | 0.360 |
Why?
|
| Humans | 57 | 2024 | 270713 | 0.330 |
Why?
|
| Oncogenes | 3 | 2021 | 697 | 0.310 |
Why?
|
| Genes, BRCA2 | 1 | 2010 | 322 | 0.310 |
Why?
|
| Genomics | 4 | 2024 | 2832 | 0.300 |
Why?
|
| Heterozygote | 1 | 2010 | 1057 | 0.290 |
Why?
|
| Genetic Variation | 1 | 2015 | 2157 | 0.280 |
Why?
|
| Mice | 13 | 2024 | 35421 | 0.280 |
Why?
|
| Molecular Targeted Therapy | 1 | 2016 | 2396 | 0.270 |
Why?
|
| Tumor Suppressor Proteins | 3 | 2024 | 1901 | 0.260 |
Why?
|
| Carcinoma, Pancreatic Ductal | 2 | 2022 | 1831 | 0.250 |
Why?
|
| Cell Line, Tumor | 10 | 2024 | 14878 | 0.250 |
Why?
|
| Small Cell Lung Carcinoma | 2 | 2020 | 417 | 0.250 |
Why?
|
| Antibodies, Monoclonal, Humanized | 7 | 2020 | 3427 | 0.240 |
Why?
|
| Neoplasm Proteins | 1 | 2016 | 3345 | 0.240 |
Why?
|
| Penicillium | 1 | 2004 | 3 | 0.240 |
Why?
|
| Tumor Microenvironment | 6 | 2024 | 3054 | 0.240 |
Why?
|
| Drugs, Chinese Herbal | 1 | 2005 | 62 | 0.240 |
Why?
|
| Liver Failure, Acute | 1 | 2005 | 98 | 0.230 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2024 | 262 | 0.220 |
Why?
|
| DNA Helicases | 2 | 2023 | 459 | 0.220 |
Why?
|
| Communicable Diseases, Emerging | 1 | 2004 | 82 | 0.220 |
Why?
|
| Aniline Compounds | 3 | 2024 | 206 | 0.220 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2004 | 189 | 0.220 |
Why?
|
| Animals | 14 | 2024 | 61357 | 0.220 |
Why?
|
| Ipilimumab | 3 | 2023 | 765 | 0.210 |
Why?
|
| Programmed Cell Death 1 Receptor | 5 | 2022 | 1095 | 0.210 |
Why?
|
| Disease Models, Animal | 2 | 2018 | 7317 | 0.200 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2024 | 503 | 0.200 |
Why?
|
| 2-Chloroadenosine | 1 | 2021 | 38 | 0.190 |
Why?
|
| Indoles | 2 | 2024 | 1029 | 0.190 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2024 | 3929 | 0.190 |
Why?
|
| Tumor Suppressor Protein p53 | 4 | 2020 | 3656 | 0.190 |
Why?
|
| Antineoplastic Agents, Immunological | 3 | 2020 | 1337 | 0.180 |
Why?
|
| Mycoses | 1 | 2004 | 393 | 0.180 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2024 | 1127 | 0.180 |
Why?
|
| Bone Morphogenetic Protein 7 | 1 | 2020 | 61 | 0.180 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 2022 | 199 | 0.180 |
Why?
|
| Prognosis | 7 | 2023 | 22528 | 0.170 |
Why?
|
| Phospholipase D | 1 | 2019 | 26 | 0.170 |
Why?
|
| Pancreatic Neoplasms | 3 | 2022 | 5258 | 0.170 |
Why?
|
| Bites and Stings | 1 | 2020 | 44 | 0.170 |
Why?
|
| Antibodies, Bispecific | 1 | 2023 | 282 | 0.170 |
Why?
|
| Antibodies, Monoclonal | 3 | 2024 | 4468 | 0.160 |
Why?
|
| Aged, 80 and over | 9 | 2024 | 31116 | 0.160 |
Why?
|
| Circulating Tumor DNA | 1 | 2022 | 277 | 0.160 |
Why?
|
| Middle Aged | 18 | 2024 | 90533 | 0.160 |
Why?
|
| Consolidation Chemotherapy | 1 | 2019 | 153 | 0.160 |
Why?
|
| Male | 18 | 2024 | 128479 | 0.150 |
Why?
|
| Adenosine Triphosphate | 2 | 2019 | 580 | 0.150 |
Why?
|
| T-Lymphocytes | 2 | 2024 | 3945 | 0.150 |
Why?
|
| Hepatitis C, Chronic | 1 | 2023 | 472 | 0.150 |
Why?
|
| ADP-ribosyl Cyclase 1 | 1 | 2018 | 149 | 0.150 |
Why?
|
| Hepatitis C | 1 | 2023 | 548 | 0.150 |
Why?
|
| Transcription Factors | 3 | 2023 | 5415 | 0.150 |
Why?
|
| Chemoradiotherapy | 3 | 2022 | 2037 | 0.150 |
Why?
|
| Aged | 14 | 2024 | 73613 | 0.140 |
Why?
|
| Female | 20 | 2024 | 148885 | 0.140 |
Why?
|
| Glutamine | 1 | 2019 | 325 | 0.140 |
Why?
|
| Cellular Reprogramming | 1 | 2019 | 203 | 0.140 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2023 | 1704 | 0.140 |
Why?
|
| Thoracic Neoplasms | 1 | 2020 | 363 | 0.140 |
Why?
|
| Adult | 14 | 2024 | 82041 | 0.140 |
Why?
|
| Adenocarcinoma | 1 | 2015 | 7920 | 0.140 |
Why?
|
| Genes, erbB-1 | 1 | 2016 | 104 | 0.140 |
Why?
|
| Liver Transplantation | 1 | 2005 | 1188 | 0.130 |
Why?
|
| Neoadjuvant Therapy | 3 | 2024 | 5246 | 0.130 |
Why?
|
| Cluster Analysis | 2 | 2015 | 1076 | 0.130 |
Why?
|
| AMP-Activated Protein Kinases | 2 | 2016 | 393 | 0.130 |
Why?
|
| Neutrophil Infiltration | 1 | 2016 | 105 | 0.130 |
Why?
|
| Single-Blind Method | 1 | 2016 | 420 | 0.130 |
Why?
|
| Drug Approval | 1 | 2016 | 174 | 0.130 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 2016 | 163 | 0.120 |
Why?
|
| Nuclear Proteins | 2 | 2023 | 3435 | 0.120 |
Why?
|
| United States Food and Drug Administration | 1 | 2016 | 323 | 0.120 |
Why?
|
| Disease-Free Survival | 4 | 2023 | 10268 | 0.120 |
Why?
|
| Disease Progression | 2 | 2016 | 6881 | 0.120 |
Why?
|
| Mesothelioma | 1 | 2020 | 558 | 0.120 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 9 | 2023 | 16741 | 0.120 |
Why?
|
| Drug Eruptions | 1 | 2016 | 271 | 0.120 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2016 | 216 | 0.120 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2016 | 368 | 0.110 |
Why?
|
| Radiosurgery | 1 | 2023 | 1389 | 0.110 |
Why?
|
| Point Mutation | 1 | 2016 | 785 | 0.110 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2016 | 626 | 0.110 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2016 | 694 | 0.110 |
Why?
|
| Melanoma | 2 | 2023 | 5599 | 0.110 |
Why?
|
| Membrane Glycoproteins | 1 | 2018 | 1091 | 0.110 |
Why?
|
| Gene Expression Profiling | 2 | 2015 | 5145 | 0.110 |
Why?
|
| Diarrhea | 1 | 2016 | 722 | 0.100 |
Why?
|
| Oxidative Stress | 2 | 2019 | 1152 | 0.100 |
Why?
|
| Precision Medicine | 2 | 2020 | 1216 | 0.100 |
Why?
|
| Binding Sites | 1 | 2016 | 2249 | 0.100 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 6 | 1 | 2011 | 15 | 0.100 |
Why?
|
| Signal Transduction | 5 | 2021 | 12042 | 0.100 |
Why?
|
| Biomarkers | 2 | 2021 | 5048 | 0.100 |
Why?
|
| Colorectal Neoplasms | 2 | 2022 | 3707 | 0.100 |
Why?
|
| Phenotype | 2 | 2020 | 6502 | 0.090 |
Why?
|
| Mutation, Missense | 1 | 2016 | 1196 | 0.090 |
Why?
|
| Transcriptome | 2 | 2020 | 1959 | 0.090 |
Why?
|
| Mice, 129 Strain | 1 | 2010 | 161 | 0.090 |
Why?
|
| Codon, Nonsense | 1 | 2010 | 159 | 0.090 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2015 | 1002 | 0.090 |
Why?
|
| Neoplasms | 3 | 2023 | 15949 | 0.080 |
Why?
|
| Meningoencephalitis | 1 | 2009 | 28 | 0.080 |
Why?
|
| Neoplasm Metastasis | 4 | 2020 | 5332 | 0.080 |
Why?
|
| Loss of Heterozygosity | 1 | 2010 | 623 | 0.080 |
Why?
|
| Enterovirus Infections | 1 | 2009 | 44 | 0.080 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2009 | 232 | 0.080 |
Why?
|
| Cell Membrane | 1 | 2011 | 880 | 0.080 |
Why?
|
| CA-19-9 Antigen | 1 | 2009 | 155 | 0.080 |
Why?
|
| Salvage Therapy | 1 | 2016 | 2124 | 0.080 |
Why?
|
| Algorithms | 1 | 2019 | 3906 | 0.080 |
Why?
|
| DNA Damage | 1 | 2016 | 1991 | 0.080 |
Why?
|
| Drug Therapy, Combination | 2 | 2023 | 2343 | 0.080 |
Why?
|
| Neoplasm Staging | 2 | 2020 | 14033 | 0.070 |
Why?
|
| Gene Silencing | 1 | 2010 | 825 | 0.070 |
Why?
|
| Gene Expression | 1 | 2015 | 3606 | 0.070 |
Why?
|
| Biomarkers, Tumor | 5 | 2023 | 10726 | 0.070 |
Why?
|
| Cytokines | 1 | 2016 | 2803 | 0.070 |
Why?
|
| Protein Kinases | 1 | 2011 | 889 | 0.070 |
Why?
|
| Brain Neoplasms | 1 | 2023 | 4968 | 0.070 |
Why?
|
| Ephedra sinica | 1 | 2005 | 1 | 0.060 |
Why?
|
| Inflammation | 1 | 2015 | 2491 | 0.060 |
Why?
|
| Plant Preparations | 1 | 2005 | 29 | 0.060 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2020 | 10404 | 0.060 |
Why?
|
| Retrospective Studies | 6 | 2024 | 39959 | 0.060 |
Why?
|
| RNA Interference | 3 | 2016 | 1381 | 0.060 |
Why?
|
| Antimalarials | 1 | 2004 | 55 | 0.060 |
Why?
|
| Alleles | 1 | 2010 | 2598 | 0.060 |
Why?
|
| United States | 2 | 2023 | 15828 | 0.060 |
Why?
|
| Lactates | 1 | 2023 | 122 | 0.050 |
Why?
|
| Sustained Virologic Response | 1 | 2023 | 63 | 0.050 |
Why?
|
| Viremia | 1 | 2023 | 157 | 0.050 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2020 | 9048 | 0.050 |
Why?
|
| DNA-Binding Proteins | 1 | 2015 | 4992 | 0.050 |
Why?
|
| Transfection | 2 | 2021 | 3109 | 0.050 |
Why?
|
| Drug Repositioning | 1 | 2021 | 52 | 0.050 |
Why?
|
| Fever | 1 | 2004 | 517 | 0.050 |
Why?
|
| Cell Proliferation | 3 | 2021 | 7232 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase 14 | 1 | 2020 | 22 | 0.050 |
Why?
|
| Molecular Docking Simulation | 1 | 2021 | 162 | 0.050 |
Why?
|
| Smad1 Protein | 1 | 2020 | 35 | 0.050 |
Why?
|
| Follistatin | 1 | 2020 | 55 | 0.050 |
Why?
|
| RAW 264.7 Cells | 1 | 2020 | 58 | 0.050 |
Why?
|
| Mice, Nude | 2 | 2019 | 4332 | 0.040 |
Why?
|
| Hepacivirus | 1 | 2023 | 423 | 0.040 |
Why?
|
| Oxidation-Reduction | 1 | 2021 | 697 | 0.040 |
Why?
|
| Virus Replication | 1 | 2023 | 762 | 0.040 |
Why?
|
| Structure-Activity Relationship | 1 | 2021 | 975 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 1 | 2010 | 7052 | 0.040 |
Why?
|
| Ligands | 1 | 2021 | 1007 | 0.040 |
Why?
|
| Receptors, Purinergic P1 | 1 | 2018 | 29 | 0.040 |
Why?
|
| Smokers | 1 | 2019 | 154 | 0.040 |
Why?
|
| Glutaminase | 1 | 2019 | 70 | 0.040 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2009 | 1740 | 0.040 |
Why?
|
| Neurons | 1 | 2009 | 2450 | 0.040 |
Why?
|
| Forkhead Transcription Factors | 1 | 2022 | 762 | 0.040 |
Why?
|
| Exons | 1 | 2021 | 1388 | 0.040 |
Why?
|
| Gene Knockdown Techniques | 1 | 2020 | 1072 | 0.040 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2019 | 341 | 0.040 |
Why?
|
| Mice, Inbred NOD | 1 | 2019 | 896 | 0.030 |
Why?
|
| Macrophages | 1 | 2023 | 1334 | 0.030 |
Why?
|
| Homeostasis | 1 | 2021 | 926 | 0.030 |
Why?
|
| A549 Cells | 1 | 2016 | 127 | 0.030 |
Why?
|
| Induction Chemotherapy | 1 | 2019 | 679 | 0.030 |
Why?
|
| Antiviral Agents | 1 | 2023 | 1246 | 0.030 |
Why?
|
| Recurrence | 1 | 2004 | 4878 | 0.030 |
Why?
|
| Tretinoin | 1 | 2018 | 632 | 0.030 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2020 | 1044 | 0.030 |
Why?
|
| Blotting, Western | 2 | 2011 | 3568 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2021 | 2033 | 0.030 |
Why?
|
| Prevalence | 1 | 2023 | 3395 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2020 | 1098 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2019 | 1825 | 0.030 |
Why?
|
| Apoptosis | 2 | 2019 | 7755 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2018 | 1355 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2019 | 2419 | 0.030 |
Why?
|
| Interferon-gamma | 1 | 2018 | 1169 | 0.030 |
Why?
|
| Cell Line | 2 | 2011 | 5313 | 0.030 |
Why?
|
| Energy Metabolism | 1 | 2019 | 988 | 0.030 |
Why?
|
| Cisplatin | 1 | 2020 | 2508 | 0.030 |
Why?
|
| Proteomics | 1 | 2020 | 1425 | 0.030 |
Why?
|
| Prenylation | 1 | 2011 | 5 | 0.030 |
Why?
|
| Fluorescence Recovery After Photobleaching | 1 | 2011 | 16 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2020 | 2560 | 0.030 |
Why?
|
| Lipoylation | 1 | 2011 | 9 | 0.030 |
Why?
|
| Guanine Nucleotide Dissociation Inhibitors | 1 | 2011 | 15 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2018 | 2413 | 0.020 |
Why?
|
| Intracellular Membranes | 1 | 2011 | 117 | 0.020 |
Why?
|
| Hep G2 Cells | 1 | 2011 | 146 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2019 | 5759 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2023 | 9053 | 0.020 |
Why?
|
| Fluorescence Resonance Energy Transfer | 1 | 2011 | 92 | 0.020 |
Why?
|
| Gene Regulatory Networks | 1 | 2015 | 677 | 0.020 |
Why?
|
| Golgi Apparatus | 1 | 2011 | 151 | 0.020 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2016 | 1032 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2018 | 1656 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2020 | 2363 | 0.020 |
Why?
|
| GTP-Binding Proteins | 1 | 2011 | 340 | 0.020 |
Why?
|
| Age Factors | 1 | 2020 | 5441 | 0.020 |
Why?
|
| Checkpoint Kinase 1 | 1 | 2011 | 169 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2011 | 687 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2021 | 33847 | 0.020 |
Why?
|
| Microscopy, Confocal | 1 | 2011 | 660 | 0.020 |
Why?
|
| Computational Biology | 1 | 2015 | 1295 | 0.020 |
Why?
|
| Cerebellar Ataxia | 1 | 2009 | 72 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2021 | 9463 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2020 | 9281 | 0.020 |
Why?
|
| Leucovorin | 1 | 2009 | 345 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2009 | 818 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2011 | 1458 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2009 | 878 | 0.020 |
Why?
|
| Camptothecin | 1 | 2009 | 540 | 0.020 |
Why?
|
| Organoplatinum Compounds | 1 | 2009 | 707 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2011 | 4532 | 0.020 |
Why?
|
| Deoxycytidine | 1 | 2011 | 1389 | 0.020 |
Why?
|
| Protein Binding | 1 | 2011 | 3472 | 0.020 |
Why?
|
| Bevacizumab | 1 | 2009 | 967 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2019 | 13419 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2011 | 6639 | 0.010 |
Why?
|
| Fluorouracil | 1 | 2009 | 1990 | 0.010 |
Why?
|
| Rituximab | 1 | 2009 | 1594 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2011 | 1944 | 0.010 |
Why?
|
| Young Adult | 1 | 2021 | 22243 | 0.010 |
Why?
|
| MicroRNAs | 1 | 2015 | 2882 | 0.010 |
Why?
|
| Adolescent | 1 | 2023 | 32689 | 0.010 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2009 | 1270 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2009 | 4966 | 0.010 |
Why?
|